Walmart inks deal with Lilly to offer pharmacy patients Humulin
INDIANAPOLIS The nation’s largest retailer has teamed up with a drug company to provide an affordable insulin option for people with diabetes.
Lilly’s Humulin will be offered by mid-September to Walmart pharmacy patients under the dual-branded name Humulin ReliOn, including 10 mL vials of Humulin R U-100, Humulin N and Humulin 70/30 formulations.
"With diabetes reaching epidemic proportions in America, it’s more important than ever for participants in the healthcare system to work together to provide solutions to help people successfully manage this condition," said Keith Johns, Lilly’s senior director for insulins in the United States. "At Lilly, we strive to provide innovative, cost-effective therapies that help patients manage their diabetes. And as the nation’s largest retailer, Walmart touches more consumers than any other retail organization in the country. This collaboration offers a unique opportunity to provide a low-cost therapy to large numbers of people affected by diabetes."
Along with Humulin ReliOn insulin, Walmart also offers $9 diabetes management products, including the ReliOn Ultima blood glucose meter, the ReliOn Ultima blood glucose test strips (20 ct) and the ReliOn A1c test (glycated hemoglobin).
"Our ReliOn diabetes management products offer customers access to quality, affordable products that allow our customers to save money and live better, healthier lives," said Sandy Kinsey, Walmart’s VP pharmacy merchandising, health and wellness. "With this new offering of Humulin ReliOn insulin, Walmart underscores our commitment to helping people affected by diabetes manage their healthcare needs."
A1c readings may not be accurate for some ethnic groups, study finds
NEW YORK The hemoglobin A1c test may not provide accurate results for elderly Asians, according to published reports about a new study.
The American Diabetes Association said the test works when doctors use an A1c reading of 6.5% to indicate diabetes, but the study, conducted in Singapore, found that the cutoff often misses the disease in older Asians. The study was conducted on participants between the ages of 20 and 93 years.
The study’s findings were scheduled to be presented Sunday at the Endocrine Society’s annual meeting in San Diego, according to the reports.
Valeant, Biovail to merge
TORONTO U.S. drug maker Valeant and Canadian drug maker Biovail will merge, the two companies said Monday.
The combined company will carry the name Valeant Pharmaceuticals International but will have its headquarters in Mississauga, Ontario. Valeant is currently based in Aliso Viejo, Calif.
Under the agreement, Valeant stockholders will receive $16.77 per share immediately before the merger’s closing and, after its closing, 1.78 shares of Biovail stock for every share of Valeant stock they own. After the merger closes, Biovail shareholders will own around 50.5% and Valeant shareholders will own 49.5% of the combined company.
Biovail is known mostly for such specialty drugs as the antidepressant Wellbutrin XL (bupropion), while Valeant’s range of branded and branded generic drugs include the acne treatment Acanya Gel (clindamycin phosphate and benzoyl peroxide).
Valeant CEO J. Michael Pearson will reside in Barbados as the new CEO, while Biovail CEO Bill Wells will be nonexecutive chairman. The company’s 11-member board of directors will include five representatives from Biovail, five from Valeant and one independent Canadian resident director.
“This compelling combination will create tremendous value for stockholders of both companies as our business benefits from cost savings, greater scale, efficiencies from extending Biovail’s corporate structure and enhanced financial strength and flexibility,” Pearson said.